oral semaglutide clinical trials 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial The Importance of Patient-Reported Outcomes

Aging Cell 17 , e12695 (2018)

Let's find your path forward

With tirzepatide, weight loss ranged from 7 to 13 kg (15.4 to 28.6 lb). In a 40-week Phase 3 trial with over 1,500 participants, Mounjary (or tizepatide) outperformed semaglutide (Ozempic) by providing A1C reduction of almost 2.3% when compared to semaglutide A1C reduction of only 1.9%

Are you tired of online weight loss solutions that promise the moon but dont produce meaningful change

Limitations An inherent limitation of both studies is that cohorts were comprised of patients engaged with healthcare systems, favouring individuals who seek or receive care

International Journal of Molecular Sciences , 26(8), 3632.